Comprehensive Stock Comparison
Compare PMGC Holdings Inc. (ELAB) vs Seres Therapeutics, Inc. (MCRB) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  MCRB | 448.4% revenue growth vs ELAB's 44.1% |
| Quality / Margins | MCRB | 15.4% net margin vs ELAB's -253.1% |
| Stability / Safety | MCRB | Beta 1.21 vs ELAB's 1.74 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | MCRB | -40.3% vs ELAB's -96.5% |
| Efficiency (ROA) | MCRB | 3.8% ROA vs ELAB's -44.6%, ROIC -180.9% vs -82.7% |
Who Each Stock Is For
Income & stability
MCRBbeta 1.21
Growth exposure
MCRBRev growth 448.4%, EPS growth -6.2%
Long-term compounding (10Y)
MCRB-98.5% 10Y total return vs ELAB's -100.0%
Sleep-well-at-night portfolio
MCRBLower volatility, beta 1.21, current ratio 0.94x
Defensive / Recession hedge
MCRBBeta 1.21, current ratio 0.94x
Business Model
What each company does and how it makes money
PMGC Holdings is a biopharmaceutical company developing novel aesthetic medicines and therapeutic products, with a focus on engineered probiotics for muscle preservation during weight loss treatments. It generates revenue primarily through research and development activities, investment operations, and potential future commercialization of its lead product EL-22 — a first-in-class probiotic targeting obesity-related muscle loss. The company's competitive advantage lies in its proprietary engineered probiotic technology platform addressing an emerging need in the rapidly growing GLP-1 weight loss market.
Seres Therapeutics is a microbiome therapeutics company developing bacterial consortia treatments for serious diseases. It generates revenue primarily through collaboration agreements and milestone payments — notably with Nestlé Health Science — while advancing its lead candidate SER-109 toward FDA approval for recurrent C. difficile infection. The company's key advantage is its proprietary platform for rationally designing bacterial consortia that functionally interact with human biology, creating a technical moat in the emerging microbiome therapeutics field.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ELAB 2MCRB 2ELAB3/5 metricsELAB5/7 metricsMCRB5/6 metricsMCRB2/2 metricsELAB leads in 2 of 6 categories (Financial Metrics, Profitability & Efficiency). MCRB leads in 2 (Total Returns, Risk & Volatility). 1 tied.
Financial Metrics (TTM)
MCRB and ELAB operate at a comparable scale, with $351,000 and -$1M in trailing revenue. MCRB is the more profitable business, keeping 15.4% of every revenue dollar as net income compared to ELAB's -2.5%.
| Metric | ELABPMGC Holdings Inc. | MCRBSeres Therapeutic… |
|---|---|---|
| RevenueTrailing 12 months | -$1M | $351,000 |
| EBITDAEarnings before interest/tax | -$4M | -$99M |
| Net IncomeAfter-tax profit | -$7M | $5M |
| Free Cash FlowCash after capex | -$7M | -$23M |
| Gross MarginGross profit ÷ Revenue | +72.8% | -50.1% |
| Operating MarginEBIT ÷ Revenue | -75.7% | -294.7% |
| Net MarginNet income ÷ Revenue | -2.5% | +15.4% |
| FCF MarginFCF ÷ Revenue | -2.2% | -66.6% |
| Rev. Growth (YoY)Latest quarter vs prior year | -45.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +100.0% | +112.3% |
Valuation Metrics
| Metric | ELABPMGC Holdings Inc. | MCRBSeres Therapeutic… |
|---|---|---|
| Market CapShares × price | $23,875 | $80M |
| Enterprise ValueMkt cap + debt − cash | -$4M | $141M |
| Trailing P/EPrice ÷ TTM EPS | -0.00x | -0.48x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 0.01x | — |
| Price / BookPrice ÷ Book value/share | 0.00x | 5.15x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
MCRB delivers a 12.3% return on equity — every $100 of shareholder capital generates $12 in annual profit, vs $-78 for ELAB. On the Piotroski fundamental quality scale (0–9), ELAB scores 4/9 vs MCRB's 2/9, reflecting mixed financial health.
| Metric | ELABPMGC Holdings Inc. | MCRBSeres Therapeutic… |
|---|---|---|
| ROE (TTM)Return on equity | -78.4% | +12.3% |
| ROA (TTM)Return on assets | -44.6% | +3.8% |
| ROICReturn on invested capital | -82.7% | -180.9% |
| ROCEReturn on capital employed | -33.7% | -67.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 2 |
| Debt / EquityFinancial leverage | — | 6.65x |
| Net DebtTotal debt minus cash | -$4M | $61M |
| Cash & Equiv.Liquid assets | $4M | $31M |
| Total DebtShort + long-term debt | $0 | $92M |
| Interest CoverageEBIT ÷ Interest expense | -17.68x | — |
Total Returns (with DRIP)
A $10,000 investment in MCRB five years ago would be worth $240 today (with dividends reinvested), compared to $1 for ELAB. Over the past 12 months, MCRB leads with a -40.3% total return vs ELAB's -96.5%. The 3-year compound annual growth rate (CAGR) favors MCRB at -56.4% vs ELAB's -96.0% — a key indicator of consistent wealth creation.
| Metric | ELABPMGC Holdings Inc. | MCRBSeres Therapeutic… |
|---|---|---|
| YTD ReturnYear-to-date | -26.1% | -39.7% |
| 1-Year ReturnPast 12 months | -96.5% | -40.3% |
| 3-Year ReturnCumulative with dividends | -100.0% | -91.7% |
| 5-Year ReturnCumulative with dividends | -100.0% | -97.6% |
| 10-Year ReturnCumulative with dividends | -100.0% | -98.5% |
| CAGR (3Y)Annualised 3-year return | -96.0% | -56.4% |
Risk & Volatility
MCRB is the less volatile stock with a 1.21 beta — it tends to amplify market swings less than ELAB's 1.74 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. MCRB currently trades 30.5% from its 52-week high vs ELAB's 3.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ELABPMGC Holdings Inc. | MCRBSeres Therapeutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.74x | 1.21x |
| 52-Week HighHighest price in past year | $30.50 | $29.98 |
| 52-Week LowLowest price in past year | $1.01 | $6.53 |
| % of 52W HighCurrent price vs 52-week peak | +3.4% | +30.5% |
| RSI (14)Momentum oscillator 0–100 | 16.2 | 32.0 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 70K |
Analyst Outlook
| Metric | ELABPMGC Holdings Inc. | MCRBSeres Therapeutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $1.25 |
| # AnalystsCovering analysts | — | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Nov 23 | Mar 26 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | 100 | 0.01 | -100.0% |
| Seres Therapeutics,… (MCRB) | 100 | 41.87 | -58.1% |
Seres Therapeutics,… (MCRB) returned -98% over 5 years vs PMGC Holdings Inc. (ELAB)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | $0.00 | $2M | — |
| Seres Therapeutics,… (MCRB) | $0.00 | $0.00 | — |
Seres Therapeutics, Inc.'s revenue grew from $0M (2015) to $0M (2024) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | -948.9% | -2.5% | +99.7% |
| Seres Therapeutics,… (MCRB) | -4.2% | -45.2% | -975.5% |
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| PMGC Holdings Inc. (ELAB) | -0.08 | -274.68 | -332442.4% |
| Seres Therapeutics,… (MCRB) | -46.6 | -18.86 | +59.5% |
Seres Therapeutics, Inc.'s EPS grew from $-46.60 (2015) to $-18.86 (2024).
Chart 5Free Cash Flow — 5 Years
PMGC Holdings Inc. generated $-5M FCF in 2024 (-691% vs 2021). Seres Therapeutics, Inc. generated $-149M FCF in 2024 (-5077% vs 2021).
ELAB vs MCRB: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is ELAB or MCRB a better buy right now?
Analysts rate Seres Therapeutics, Inc. (MCRB) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ELAB or MCRB?
Over the past 5 years, Seres Therapeutics, Inc. (MCRB) delivered a total return of -97.6%, compared to -100.0% for PMGC Holdings Inc. (ELAB). A $10,000 investment in MCRB five years ago would be worth approximately $240 today (assuming dividends reinvested). Over 10 years, the gap is even starker: MCRB returned -98.5% versus ELAB's -100.0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ELAB or MCRB?
By beta (market sensitivity over 5 years), Seres Therapeutics, Inc. (MCRB) is the lower-risk stock at 1.21β versus PMGC Holdings Inc.'s 1.74β — meaning ELAB is approximately 43% more volatile than MCRB relative to the S&P 500.
04Which has better profit margins — ELAB or MCRB?
Seres Therapeutics, Inc. (MCRB) is the more profitable company, earning 1537% net margin versus -253.1% for PMGC Holdings Inc. — meaning it keeps 1537% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELAB leads at -75.7% versus -294.7% for MCRB. At the gross margin level — before operating expenses — ELAB leads at 72.8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ELAB or MCRB?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ELAB or MCRB better for a retirement portfolio?
For long-horizon retirement investors, Seres Therapeutics, Inc. (MCRB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.21)). PMGC Holdings Inc. (ELAB) carries a higher beta of 1.74 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCRB: -98.5%, ELAB: -100.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ELAB and MCRB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.